Fred Hutch Cancer Center | Strategic Alliance Partners

Expert shares the latest advancements in CAR T therapy and novel treatments for myeloma, addressing access challenges and promising new options.

An expert discusses CAR T therapy's potential in treating relapsed multiple myeloma, highlighting long-term remissions and access challenges.

The multiple myeloma landscape is evolving, with bispecific T-cell engagers offering hope.

Advancements in treatment include immune checkpoint inhibitors and BRAF/MEK inhibitors, though resistance remains a challenge, with lifileucel recently approved for previously treated metastatic cases.

Treatment of advanced/metastatic urothelial cancer has changed dramatically in recent years. This review discusses the use, risks, and benefits of several novel therapies for this indication.

This review discusses the prevalence, mechanisms of development, and evolving treatment landscape in chronic lymphocytic leukemia.

Approval of a novel antibody-drug conjugate ushers in new second-line option.

Atrial fibrillation, bleeding, infection, and other adverse events may occur with this therapy.

Pharmacy Times® interviewed Petros Grivas, MD, PhD, associate professor at the University of Washington and Fred Hutchinson Cancer Research Center and a medical oncologist at Seattle Cancer Care Alliance, on the work of the COVID-19 and Cancer Consortium.

Pharmacy Times® interviewed Petros Grivas, associate professor at the University of Washington and Fred Hutchinson Cancer Research Center and a medical oncologist at Seattle Cancer Care Alliance, on the value of the pharmacist in the treatment of patients with cancer during COVID-19.